Skip to main content
Clinical Trials/ACTRN12610000090011
ACTRN12610000090011
Not yet recruiting
未知

utrigenomic risk profiles for Mild Cognitive Impairment, Alzheimer's disease and Parkinson's disease

Commonwealth Scientific and Industrial Research Organisation0 sites900 target enrollmentJanuary 27, 2010

Overview

Phase
未知
Intervention
Not specified
Conditions
eurodegenerative diseases
Sponsor
Commonwealth Scientific and Industrial Research Organisation
Enrollment
900
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 27, 2010
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Control Group:
  • Male or female, Aged 55 and above, Not clinically diagnosed with mild cognitive impairment, Alzheimer's disease and Parkinson's, No family history of mild cognitive impairment, Alzheimer's disease and Parkinson's disease
  • Mild cognitive impairment Group:
  • Male or female, Aged 55 and above, Clinically diagnosed with mild cognitive impairment
  • Alzheimer's disease Group:
  • Male or female, Aged 55 and above, Clinically diagnosed with Alzheimer's disease
  • Parkinson's disease Group:
  • Male or female, Aged 55 or above, Clinically diagnosed with Parkinson's disease

Exclusion Criteria

  • Control Group:
  • Patients who are undergoing chemotherapy,radiotherapy treatment for cancer, patients that are supplementing with above recommended dietary intakes of micronutrients associated with genome maintenance
  • Mild cognitive impairment Group:
  • Patients who are undergoing chemotherapy, radiotherapy treatment for cancer, patients that are supplementing with above recommended dietary intakes of micronutrients associated with genome maintenance
  • Alzheimer's disease Group:
  • Patients who are undergoing chemotherapy, radiotherapy treatment for cancer, patients that are supplementing with above recommended dietary intakes of micronutrients associated with genome maintenance
  • Parkinson's disease Group:
  • Patients who are undergoing chemotherapy, radiotherapy treatment for cancer, patients that are supplementing with above recommended dietary intakes of micronutrients associated with genome maintenance

Outcomes

Primary Outcomes

Not specified

Similar Trials